Last updated: February 14, 2026
Product Overview
NDC 59630-0755 corresponds to Xyrem (sodium oxybate), a centrally acting depressant indicated for narcolepsy with cataplexy, excessive daytime sleepiness, and treatment-resistant narcolepsy. Approved by the FDA in 2002, Xyrem is marketed by Jazz Pharmaceuticals.
Market Landscape
-
Market Size & Growth: The global narcolepsy drugs market was valued at approximately $400 million in 2022, with an expected compound annual growth rate (CAGR) of 5-7% over the next five years (source: Grand View Research). Xyrem accounts for roughly 60% of this market.
-
Patient Population: Estimated at 200,000 to 300,000 patients in the US, with a significant proportion under diagnosis or receiving off-label treatments. The number of diagnosed narcolepsy cases is growing, driven by increased awareness and diagnostic capabilities.
-
Competitors: Main alternatives include stimulant medications (e.g., modafinil, amphetamines), off-label use of antidepressants, and emerging therapies like low-sodium oxybate variants and investigational agents. The entry of generics is limited due to patent protections, but patent expirations for some formulations could impact pricing.
Pricing History and Current Status
-
Historical Prices: As of 2022, the wholesale acquisition cost (WAC) for Xyrem was approximately $1,300 per 60 mL bottle (100 mg/mL concentration), with a typical patient regimen of 4.5 g nightly, equating to roughly $84,000 annually per patient.
-
Pricing Trends: Slight increases over the past decade, maintaining a premium position due to the drug’s patent exclusivity, regulatory barriers, and brand recognition.
-
Reimbursements & Copays: Insurance coverage is widespread, but high copays can impact patient access and adherence, influencing market dynamics.
Regulatory & Patent Environment
-
Patents & Exclusivity: Jazz Pharmaceuticals holds method-of-use and formulation patents extending into 2027. The potential for generic entry hinges on patent challenges and patent term extensions.
-
Regulation & Approvals: The drug is designated as a Schedule III controlled substance, complicating manufacturing and pharmacy dispensing logistics—factors that sustain market entry barriers for generic manufacturers.
Future Price Projections
-
Near-term (1-3 years): Prices are expected to stay stable barring significant patent litigation or regulatory change. Slight increases in line with inflation and healthcare cost trends are probable.
-
Medium to Long-term (3-7 years): Potential reduction in price if patents are challenged successfully and generics enter the market, which could lower prices by 30-50%. If patent exclusivity persists, prices could remain flat or increase marginally.
-
Impact of New Formulations: Pending development of non-sodium oxybate formulations and alternative delivery mechanisms (e.g., extended-release) could influence primary market shares, altering pricing strategies.
Market Entry & Competitive Risks
-
Biosimilar or generic versions could challenge the premium pricing of Xyrem. The timeline hinges on patent litigation, exclusivity periods, and regulatory pathways.
-
If competitors introduce effective and less restrictive formulations, pricing could face downward pressure sooner.
Key Takeaways
-
Xyrem (NDC 59630-0755) dominates the narcolepsy treatment market with a high price point maintained through patent protections and regulatory barriers.
-
Market growth correlates with increased diagnosis and awareness; competition remains limited but is evolving.
-
Short-term pricing is stable; long-term price declines depend on patent expiry and generic entry.
-
Patient access influences revenue; high copayment burdens affect overall market size.
-
Innovations in drug delivery and alternative formulations could reshape competitive dynamics and pricing.
FAQs
1. What are main factors influencing the future price of Xyrem? Government patent protections, regulatory environment, generic entry, competition from alternative therapies, and manufacturing costs.
2. How will patent expiration affect market prices? Patent expiry around 2027 could introduce generics, leading to a significant decrease exceeding 50% unless extension or new formulations are introduced.
3. Are there any new formulations or substitutes in development? Yes, research continues into non-sodium oxybate drugs and extended-release options, which could impact branding and pricing strategies.
4. How does insurance coverage impact the market? High copays and insurance restrictions limit patient access and adherence, affecting overall revenue.
5. What role do regulatory hurdles play in pricing? As a Schedule III controlled substance, its prescribing and dispensing are tightly regulated, which acts as a barrier to rapid market entry of competitors and impacts pricing stability.
Citations
[1] Grand View Research, "Narcolepsy Drugs Market Size & Trends," 2022.
